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ABSTRACT 
Objective: This study is an attempt to identifying an effective fluoroquinolones (FQ) s against STAPHYLOCOCCUS AUREUS (S. aureus) by in silico 
analysis of 150 (FQ) compounds using iGemDock v2.1 tool.  
Methods: Structure of DNA gyrase (2XCT) was retrieved from the Protein Data Bank (PDB) and the structures of (FQ) compounds were selected 
from literature survey of 400 novel compounds and the physical, chemical and molecular characteristics of each compound were obeyed for drug-
relevant properties based on “Lipinski’s rule of five, then a total of 150 (FQ)s were docked against the protein of the 2XCT enzyme. 
Results: From this study, it was found that the compound (1) [(3R,7E)-9-fluoro-7-(isonicotinoylhydrazono)-3-methyl-10-(4-methylpiperazin-1-yl)-
2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid] and the compound (2) [1-cyclopropyl-6-fluoro-7-{4-[(8-hydroxyquinolin-2-
yl)methyl]piperazin-1-yl}-4-oxo-1,4-dihydroquinoline-3-carboxylic acid] showed the best interaction value against 2XCT enzyme, the binding 
energy was (-104. 58 kcal/mol), (-26. 5kcal/mol) respectively whereas the reference ciprofloxacin (CIP) was (-74. 33 kcal/mol). 
Conclusion: Further in vitro studies of these compounds against the enzyme will lead a new pathway to drug discovery.  
Keywords: S. aureus, (FQ)s, 2XCT, DNA gyrase, Lipinski’s rule, iGemdock, In silico.  
© 2016 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/) 
 
INTRODUCTION 
S. aureus is an opportunistic, anaerobic Gram-positive coccal 
pathogen, found on the mucous membranes and the human skin, 
which shows extreme adaptability to antibiotic pressure [1]. It can 
cause a range of illnesses from minor skin infections to life-
threatening diseases [2], and it is still one of the five most common 
causes of nosocomial infection and community-acquired methicillin-
resistant S. aureus (MRSA) [3]. Today, the spread of multi-resistant 
bacteria becomes major concern in the hospital environment, where 
the glycopeptides, vancomycin and teicoplanin are considered as the 
last resort drugs against (MRSA) [4-6]. Therefore, the search for new 
structural ligands and novel targets of attack as a means to 
overcome bacterial resistance is an important research goal [7, 8].  
Modern approaches toward development of new potential inhibitors 
are based on knowledge of structure and function of proteins 
specific to bacteria like DNA gyrase which is member of the 
topoisomerase enzymes that are able to relax supercoiled DNA in a 
reaction coupled to the hydrolysis of ATP [9,10], whereas it is 
characteristic and essential bacterial enzyme when it is inactivated, 
it leads to bacterial cell death. For this reason, gyrases have been 
chosen as targets for antibacterial agents [11-13]. DNA gyrase 
consists of two subunits, A and B, of molecular mass 97 and 90 kDa, 
respectively, with the active enzyme being an A2B2 complex. The A 
subunit of DNA gyrase is involved in DNA breakage and reunion 
while the B subunit catalyzes the hydrolysis of ATP [14, 15]. There 
are many agents that target this enzyme such as (FQ)s coumarins, 
and cyclothialidines while all have their own limitations [16]. (FQs), 
e.g., ciprofloxacin, inhibit the DNA breakage-reunion cycle by 
forming a constant complex with DNA and the enzyme DNA gyrase 
[17]. They have gained immense importance during the last two 
decades because of their potent antibacterial activity against wide 
varieties of gram-positive and gram-negative pathogenic bacteria 
with minimum toxic side effects [18, 19]. The (FQs) were introduced in 
1980s, they have a relatively simple molecular nucleus which consists 
of a bicyclic ring structure, and there is a substitution at position N-1, a 
carboxyl group at position 3, a keto group at position 4, a fluorine atom 
at position 6 and a nitrogen heterocyclic moiety at the C-7 position 
[20-23]. To date, many (FQ)s as antibacterial agents have been 
developed and synthesized to be used in clinical trials with significant 
improvement in the antibacterial spectrum and activity [24].  
In silico methods are used to analyze the target structures for 
possible binding sites, generate candidate molecules, check for their 
drug-likeness, dock these molecules with the target, rank them 
according to their binding affinities, and further optimize the 
molecules to improve binding characteristics [25]. This work is an 
attempt to survey a number of novel (FQ)s that are synthesized in 
the last years, then do a virtual screening that allows studying the 
compounds in silico and comparing them with the reference and 
select, theoretically, the best compounds based on binding energy as 
inhibitors of DNA gyrase of S. aureus.  
MATERIALS AND METHODS 
Protein preparation 
The receptor enzyme, required for the docking study that related to 
S. aureus has been retrieved from the(PDB) which is a key resource 
in areas of structural biology, and it is a fundamental repository for 
3D structure data of large molecules [26]. The enzyme PDB ID-2XCT 
[27-30] was designated on this site and it had a resolution factor 
3.35 A°. The enzyme was downloaded then saved in pdb file format 
and the 3D of it was shown in fig. 1. We defined the active site of 
(2XCT) based on the x-ray complex structure of protein (2XCT) and 
binding ligand (CIP), fig. 2, whereas that ligand was discovered and 
developed by Bayer A. G. and subsequently approved by the US Food 
and Drug Administration (FDA) in 1987, and it was the most widely 
used of the second-generation of (FQ)s antibiotic that came into 
clinical use in the late 1980s and early 1990s [31, 32]. 
Generation and optimization of ligands 
The (FQ) s, fig. 3, which was reported here, had been selected after 
an extensive literature survey. In fact, we had selected a total of 400 
new compounds of (FQ)s [33,34,35-40,41,42,65], and they were 
drawn in the two-dimensional (2D) structures using ACD 
chemsketch software [66]. Then the compounds were saved in mol 
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format and converted to mol2 format using the OPEN BABEL 
software [67]. After that a total of 150 (FQ) compounds had been 
selected for in silico study based on “Lipinski’s rule of five”[68-69], 
where the molecular properties such as cLogp, number of hydrogen 
bond donors and acceptors and polar surface area were obtained 
from: www.molinspiration.com [70]. 
  
 
Fig. 1: (A) 3D structure of 2XCT protein, (B) the reference ligand (ciprofloxacin) 
 
 
Fig. 2: 3D Binding site of 2XCT with reference inhibitor (Ciprofloxacin) 
 
 
Fig. 3: the parent structure of fluoroquinolones 
 
Protein-ligand docking 
In this research, we used iGemdock software [71, 73] to dock the 
enzyme (2XCT) with 150 (FQ)s, which it is available for free and was 
used in various previous researches  [74-77].  
iGemdock v2. 1 
In order to carry out docking simulation of the enzyme (2XCT) with 
150 (FQ)s, we used the iGemdock v2. 1 as molecular docking tool. 
iGemdock is an integrated virtual screening (VS) environment from 
preparations through post-screening analysis with pharmacological 
interactions. iGemdock generates protein-compound interaction 
profiles by providing interactive interfaces to prepare both the 
binding site of the target enzyme and the screening compounds 
library. Then each compound in the library is docked into the 
binding site by using the in-house docking tool iGemdock. Afterward, 
iGemdock infers the pharmacological interactions and clusters the 
screening compounds for the post-screening analysis based on 
profiles of electrostatic (E), hydrogen-bonding (H), and Van der 
Waal’s (V) interactions and compound structures. Finally, iGemdock 
ranks and visualizes the screening compounds by combining the 
pharmacological interactions and energy-based-scoring function of 
iGemdock.  
Virtual screenings of the 150 compounds were performed in the 
docking tool iGemdock. The docking consisted protocol "accurate 
docking" by setting population size of 800 is set with 80 generations 
and 10 solutions. After the completion of the docking, the post-
docking analysis was performed to find the docking pose and its 
energy values. The empirical scoring function of iGemdock was 
estimated using:  
Energy = vdW+Hbond+Elec 
Here, the vdW term is van der Waal energy; H bond and Elect terms 
are hydrogen bonding, energy, and electro statistic energy, 
respectively.  
Table 1 illustrates the structure of 30 studied compounds and shows 
the structure and the IUPAC name of the compounds. 
RESULTS AND DISCUSSION 
In silico docking is the best approach to check utility of any chemical 
as a drug before going through any in vivo or in vitro analysis to 
shorten out the experiments and cost cutting. A literature survey 
was done for new compounds of (FQ)s, then a total of 150 
compounds were selected based on Lipinski’s rule of five and they 
were docked against the enzyme DNA gyrase of S. aureus using 
iGemdock to understand its interactive analysis before they have 
been proposed to study its in vitro antibacterial activity.  
The objective of the current work is to evaluate the theoretical 
antibacterial activity against S. aureus of the novel (FQ)s that 
have been synthesized in recent years by using the docking 
studies. In this perspective, synthesized compounds like that 
mentioned in table (1) were selected and (CIP), a known 
DNAgyrase inhibitor, was used as the standard, and then the 
docking studies were performed using iGemdock v2. 1, and the 
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results displayed that all the selected (FQs) showed lesser 
binding energy ranging between (-104. 58 kcal/mol) to (-47.33 
kcal/mol) as it shows in table 2 when compared with the 
standard (-74.33 kcal/mol). So, these molecular docking 
analyses could deliver the most potent 2XCT inhibitors for the 
prevention and treatment of infections caused by S. aureus. 
 
Table 1: The structure of 30 screened fluoroquinolone compounds 
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Table 2: The docking binding energy values results using iGemdock 
S. No. VW. force (kcal/mol) H Bond (kcal/mol) Elec. energy (kcal/mol) Total binding energy(kcal/mol) 
1 -90.19 -14.49 0.1 -104.58 
2 82.98 -18.42 0 -101.4 
3 -68.74 -31.14 -1.45 -101.33 
4 -73.13 -24.95 -1.15 -99.22 
5 -82.91 -15.62 0 -98.52 
6 -88.58 -9.63 0.16 -98.04 
7 -89.07 -6.6 0 -95.67 
8 -80.42 -15.17 0 -95.59 
9 -79.28 -16.19 0 -95.57 
10 -78.05 -16.58 0 -94.62 
CIP -60.38 -15.88 1.92 -47.33 
 
Post-screening analysis 
All the (FQ)s in the post-screening analysis PDB ID-2XCT, in 
comparison to the reference (CIP), were as potential antibacterial 
drugs of S. aureus with good docking energy with the target protein 
especially the compound No. 1[(3R,7E)-9-fluoro-7-(isonicotinoyl-
hydrazono)-3-methyl-10-(4-methylpiperazin-1-yl)-2,3-dihydro-7H-
[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid] and the compound 
No.2 [1-cyclopropyl-6-fluoro-7-{4-[(8-hydroxyquinolin-2-yl)methyl] 
piperazin-1-yl}-4-oxo-1,4-dihydroquinoline-3-carboxylic acid] 
which they had better drug activity, as they showed the most 
favorable binding energy whereas the first compound binds to DNA 
gyrase with high binding affinity (-104. 58 kcal/mol) and the second 
(-101. 4 kcal/mol). Our study showed that the compound No. 1 that 
was synthesized in 2013 by (Sahu Susanta K., Pandeya Surendra N.) 
and it evaluated as a new inhibitor of E coli. Whereas the compound 
No. 2 was synthesized in 2005 by(Yue-Ling Zhao, Yeh-Long Chen, et 
al.) as anti tubercular agent. Here in this study they were good agents 
against DNA gyrase of S. aureus based on binding energies, in 
comparison to the (CIP). Also the compound (3) [6-{4-[(2Z)-2-
[(aminocarbonyl) hydrazono]-2-(4-methoxyphenyl)ethyl] piperazin-
1-yl}-4-ethyl-7-fluoro-1-oxo-1,4dihydronaphthalene-2-carboxylic 
acid] and the compound (4) [4-ethyl-7-fluoro-6-{4-[(2Z)-2-hydrazono-
2-phenylethyl] piperazin-1-yl}-1-oxo-1, 4-dihydro-naphthalene-2-
carboxylic acid] that were synthesized in 2014 by (Mehul M. Patel and 
Laxman J. Patel) disappeared an acceptable energies, so they could be 
an effective against S. aureus. 
The interactions and fitness scores of the compound suggest that 
these compounds can as an antimicrobial activities drug against 
gram-positive S. aureus.  
Table 3 shows residues that are associated with the amino acids in the 
binding site of the compound No. 1 that it was the best in Elec energy and 
the reference. Fig. 4 illustrates the interactions of the compound No. 1 
with protein pocket which have the most favorable binding energy. 
 
Table 3: Pharmacological interactions and Residues involved in the binding site 
CIP Compound 1 Predicted pharmacologic interactions PDB ID 
0 -3.5 H-M GLU 435  
2XCT 
 
0 -3.5 H-S GLU 435 
0 -4.2 H-S ASP 437 
-3.5 0 H-S LYS 460 
-6.2 0 H-S ASN 475 
-12 -3.3 H-S ARG 1122 
-6.1 -7.7 V-M GLU 435 
6.6- -7.5 V-S GLU 435 
11.4- -14.4 V-M GLY 436 
0 -16.6 V-M ASP 437 
3.6- -12.8 V-S ASP 437 
-3.2 0 V-M ARG 458 
The green and grey color represents the amino acids involved in(H)hydrogen bonding and(V) van der Waals are interaction types M and S are Main 
chain and Side chain. 
 
 
Fig. 4: The compound (1) with the reference CIP and their 
interactions with the amino acids of the binding site 
Lipinski’s rule 
Lipinski et al. formulated the ’Rule of Five’ to predict drug-likeness, 
which consists of four important properties, each related to the 
number 5. The rule is based on data in the literature for a large 
number of compounds, including all known drugs that correlate 
physical properties with oral bioavailability. The compounds are 
more likely to be membrane permeable and easily absorbed by the 
body if it matches the following criteria:  
1. The molecular weight of less than 500 mg/mol 
2. Has a high lipophilicity (log p less than 5) 
3. Hydrogen bond donors less than 5 
4. Hydrogen bond acceptor is less than 10 
The rule describes molecular properties important for a drug's 
pharmacokinetics in the human body, including their Absorption, 
Distribution, Metabolism, and Excretion (ADME). The rule is important 
for drug development where a pharmacologically active lead structure 
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is optimized step-wise for increased activity and selectivity, as well as 
drug-like properties as described by Lipinski's rule.  
The table 4 depicts the values related to the Lipinski’s rule of five. 
From the table it is evident that all the ten studied compounds obey 
the Lipinski’s rule. The molecular docking studies and Lipinski’s 
rules facilitate drug development avoiding expensive post clinical 
experiments.  
Veber rule and molar refractivity  
1-Veber Rule: In particular, compounds which meet only the two 
criteria of:  
a) Rotatable bond count≤10.  
b) Polar surface area (PSA) equal to or less than 140 Å2 are 
predicted to have good oral bioavailability. 
2-Molar Refractivity: between (40-130) is used as measurement of 
the real volume of the molecule and it is also related to the forces 
which govern the ligand-receptor interactions [79]. 
The 10 high ranked lead molecules were prioritized to follow 
Lipinski’s guidelines of five, veber rule and molar refractivity based 
on the likeliness drug properties are listed in table 4. 
 
Table 4: The Lipinski’s and Veber properties of the selected 10 ligands 
MR1* PSA2 RB2* HA2* HD2* logP2# M W2* 
g/mol 
Molecular Formula1 S. No. 
40-130 140<  =10< 10< 5< 5< 500< Value to be  
126.4 112.30 4 9 2 -1.43 480.49 C25H26FN5O4 1 
130.4 98.90 5 8 2 0.679 488.51 C27H30FN5O5 2 
137.01 137.56 6 7 2 1.22 464.5 C27H30FN5O5 3 
122.69 99.23 6 7 2 0.735 450 C25H27FN4O3 4 
129.19 84.75 6 7 0 2.09 492.5 C27H29FN4O4 5 
131.04 99.41 4 8 2 -0.28 479.50 C25H25ClFN5O4 6 
115.42 136.45 6 10 3 -2.331 473.451 C23H24FN3O2 7 
125.27 84.75 6 7 0 2.69 478.5 C26H27FN4O4 8 
125.32 84.75 5 7 0 2.84 478.51 C26H27FN4O4 9 
128.74 84.75 5 7 0 1.97 450.46 C27H25FN4O4 10 
83.25 74.57 3 6 2 -1.27 331.34 C17H18FN3O3 CIP 
1-Calculated by ACD (Available Chemical Directory) 2-calculated by: www. molinspiration. Com, *PSA: Polar Surface Area,*MW: Molecular weight, 
*HD: H bond donor, *HA: H bond acceptor. *RB: rotatable bonds. *MR: Molar refractivity#Octanol/Water partition coefficient 
 
CONCLUSION 
The present study has given an insight into the searching of new 
fluoroquinolones as DNA gyrase of S. aureus inhibitors. Various in 
silico tools like Lipinski filter and molecular docking has been 
utilized to select the best compounds as antibacterial inhibitors of S. 
aureus whereas the synthesized derivative [(3R,7E)-9-fluoro-7-
(isonicotinoyl-hydrazono)-3-methyl-10-(4-methylpiperazin-1-yl)-
2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid] 
showed good antibacterial activity theoretically, then further in vitro 
studies should be applied to evaluate the biological activity. Thus, 
the in silico study has been helpful in promising molecules enabling 
the minimization of time spend for searching compounds and can be 
considered as good method for screening of novel fluoroquinolones 
to target another enzyme.  
ABBREVIATION 
(FQ)s: Fluoroquinolones (S. aureus: S staphylococcus aureus, MRSA: 
Methicillin-Resistant S. Aureus, CIP: Ciprofloxacin, iGemdock: 
iGeneric Evolutionary Method Docking, PDB: Protein Data Bank, 
ADME: Absorption, Distribution, Metabolism, and Excretion 
ACKNOWLEDGMENT 
The authors would like to thank all the management of Aleppo 
University and all the staff of Faculty of Pharmacy for assistance. 
There is no known conflict of interest associated with the 
publication and there has been no significant financial support for 
this work that could have influenced its outcome.  
CONFLICT OF INTERESTS 
Declared None 
REFERENCES 
1. Tiwari HK, Das AK, Sapkota D, Sivarajan K, Pahwa VK. 
Methicillin resistant Staphylococcus aureus prevalence and 
antibiogram in a tertiary care hospital in western Nepal. J Infect 
Dev Countries 2009;3:21-4.  
2. Chambers HF. The changing epidemiology of Staphylococcus 
aureus. Emerging Infect Dis 2001;7:182-7.  
3. Cole A, Tahk S, Oren A, Yoshioka D, Kim YH, Park A, et al. 
Determinants of S. aureus nasal carriage. Clin Diagn Lab 
Immunol 2001;6:1064-9.  
4. Robert J, Bismuth R, Jarlier V. Decreased susceptibility to 
glycopeptides in methicillin‑resistant Staphylococcus aureus. J 
Antimicrob Chemother 2006;57:506-11. 
5. Bal M, Saha B, Singh AK, Ghosh A. Identification and 
characterization ofa vancomycin‑resistant S. aureus isolated 
from Kolkata (South Asia). J Med Microbiol 2008;57:172-9. 
6. Foster JK, Joseph R, Lentino RS, Divincenzo C. Comparison of in 
vitro activity of quinolone antibiotic and vancomycin against 
gentamicin‑and methicillin‑resistant S. aureus time‑kill kinetic 
studies. Antimicrob Agents Chemother 1986;30:823-9. 
7. Gould IM, David MZ, Esposito S. New insights into meticillin-
resistant S. aureus (MRSA) pathogenesis, treatment and 
resistance. Int J Antimicrob Agents 2012;39:104-12.  
8. Brown DF, Edwards DI, Hawkey PM, Morrison D, Ridgway GL, 
Towner KJ, et al. Guidelines for the laboratory diagnosis and 
susceptibility testing of methicillin-resistant S. aureus (MRSA). J 
Antimicrob Chemother 2005;56:1000-18.  
9. Champoux JJ. DNA topoisomerases: structure, function, and 
mechanism. Annu Rev Biochem Allied Res India 2001;70:369-73.  
10. Schoeffler AJ, Berger JM. DNA topoisomerases are harnessing 
and constraining energy to govern chromosome topology. Q 
Rev Biophys 2008;41:101-41.  
11. Laponogov I, Sohi MK, Veselkov DA, Pan X-S, Sawhney R, 
Thompson AW, et al. Structural insight into the quinolone-DNA 
cleavage complex of type IIA topoisomerases. Nat Struct Mol 
Biol 2009;16:667–9.  
12. Bax DB, Chan PF, Eggleston DS, Fosberry A, Gentry DR, Gorrec 
F, et al. Type IIA topoisomerase inhibition by a new class of 
antibacterial agents. Nature 2010;466:935-9.  
13. Levine C, Hiasa H, Marians KJ. DNA Gyrase and topoisomerase 
IV: biochemical activities, physiological roles during 
chromosome replication and drug sensitivities. Biochim 
Biophys Acta Bio member 1998;1400:29-43.  
14. Gallert M, Mizuuchi K, Mary O’dea H, Nash AH. DNA gyrase: an 
enzyme that introduces superhelical turns in to DNA. Proc Natl 
Acad Sci USA 1976;73:3872-6.  
Sabbagh et al. 
Int J Pharm Pharm Sci, Vol 8, Issue 1, 67-75 
74 
15. Drlica K, Zhao X. DNA Gyrase, Topoisomerase IV, and the 4-
Quinolones. Microbiology and molecular biology reviews. 
Microbiol Mol Biol Rev 1997;61:377-92.  
16. Angehrn P, Buchmann S, Funk C, Goetschi E, Gmuender H, 
Hebeisen. “New Antibacterial agents derived from the DNA 
gyrase inhibitor cyclothialidine”. J Med Chem 2004;47:1487-93.  
17. Hooper DC. Mode of action of (FQ)s. Drugs 1999;58:6-10. 
18. Hooper DC. Mechanisms of action and resistance of older and 
newer (FQ)s. Clin Infect Dis 2000;31:24-8.  
19. Hooper DC. Mechanisms of quinolone resistance. Clin Infect Dis 
1999;2:38-55.  
20. Emami S, Shafiee A, Foroumadi A. Structural features of new 
quinolones and relationship to antibacterial activity against 
Gram-positive bacteria. Mini Rev Med Chem 2006;6:375-86. 
21. Prabodh Chander Sharma, Ankit Jain, Sandeep jain. (FQ) 
Antibacterials: a review on chemistry microbiology and therapeutic 
prospects. Acta Poloniae Pharm Drug Res 2009;66:587-98. 
22. GS Tillotson. Quinolones: structure-activity relationships and 
future predictions. J Med Microbiol 1996;44:320-4.  
23. Daniel T, W Chu, Prabhavathi B. Fernandest: structure-activity 
relationships of the (FQ)s. Am Soc Microbiol 1989;33:131-5.  
24. Roy Akhilesh, Sardar SM, Salve B, Rishi Pathak DD. Studies on 
synthesis and biological evaluation of some substituted (FQ)s. 
Int J Chem Tech Res 2009;1:34-45.  
25. Venkatachalam CM, Jiang X, Oldfield T, Waldman M, Ligand Fit. 
A novel method for the shape-directed rapid docking of ligands 
to protein active sites. J Mol Graphics Modell 2003;21:289–99.  
26. Research collaboratory for structural bioinformatics. Protein 
Data Bank; 2015. Available from http://www.pdb.org. [Last 
accessed on 26 Mar 2015]. 
27. Nikola Minovski, Andrej Perdih, Marjana Novic, Tom Solmaje. 
Cluster-based molecular docking study for in silico 
identification of novel 6-(FQ)s as potential inhibitors against 
mycobacterium tuberculosis. J Comput Chem 2013;34:790–9.  
28. Bax DB, Chan PF, Eggleston DS, Fosberry A, Gentry DR, Gorrec 
F, et al. Type IIA topoisomerase inhibition by a new class of 
antibacterial agents. Nature 2010;466:935–9.  
29. Margerrison EEC, Hopewell R, Fisher LM. The nucleotide 
sequence of the Staphylococcus aureus gyr A-gyr B locus 
ending the DNA gyrase A and B protein. J Bacteriol 
1992;174:1596-663.  
30. Brockbank SMV, Barth PT. Cloning, Sequencing, and expression 
of the DNA gyrase genes from Staphylococcus aureus. J Bacteriol 
1993;175:3269-77.  
31. Majed M, Masadeh, Karem H. Ciprofloxacin-induced 
antibacterial activity is attenuated by phosphodiesterase 
inhibitors. Curr Ther Res 2015;77:14-7. 
32. Goossens H, Ferech M, Coenen S, Stephens P, Ferech, Coenen, et 
al. "Comparison of outpatient systemic antibacterial use in 
2004 in the United States and 27 European countries". Eur 
Surveillance Antimicrobial Consumption Project Group Clin 
Infect 2007;8:1091-8. 
33. Reanau Thomas E, Sanchez Joseph P, Gage Jeffrey W, Dever A, 
Shapiro Martin A. Structure-activity relationships of the 
quinolone antibacterials against mycobacteria: effect of 
structural changes At N-1 And C-7. J Med Chem 1996;39:729-35.  
34. Baton Sandor, Timari Geza, KoczkaIstvan, Herecz Isavan. 
Synthesis and biological evaluation of N-(1-Aziridino)-6-(FQ)s. 
Bioorg Med Chem Lett 1996;13:1507-10.  
35. Hong Chang Hong, Kim Young Kwan, Chang Jay Hyok, Kim Se 
Ho, Choi Hoon, Nam Hyun Do, et al. Noval(FQ) antibacterial 
agents containing oxime-substituted (Aminomethyl) 
pyrrolidines: synthesis and antibacterial activity of 7-(4-
(Aminomethyl)-3-(Methoxyimino)Pyrrolidin-1-Yl)-
1Cyclopropyl-6-Fluoro-4-Oxo-1,4-Dihydro[1,8]Naphthyridine-
3-Carboxylic Acid. J Med Chem 1997;40:3584-93.  
36. Neito MJ, Alovero FDL, Manzo RH, Mazzieri MR. A new class of 
(FQ)s: Benzenesulfonamide (FQ)s antibacterial activity and 
SAR studies. Eur J Med Chem 1999;34,209-14.  
37. Kuo-Chang Fang, Yeh-Long Chen, Jia-Yuh Sheu, Tai-Chi Wang, 
Cherng-Chyi Tzeng. Synthesis, Antibacterial, and cytotoxic 
evaluation of certain 7-Substituted norfloxacin derivatives. J 
Med Chem 2000;43:3809-12.  
38. Chen YL, Fang KC, Sheu JY, Hsu SL, Tzeng CC. Synthesis and 
antibacterial evaluation of certain quinolone derivatives. J Med 
Chem 2001;44:2374-7.  
39. F Alovero, A Barnes, M Nieto, MR Mazzieri, RH Manzo. 
Comparative study of new benzenesulfonamide (FQ)s 
structurally related to ciprofloxacin against selected 
ciprofloxacin-susceptible and–resistant Gram-positive cocci. J 
Antimicrob Chemother 2001;48:709-12.  
40. Natesh Rameshkumar, Mohan, Ekambaram Harihara, 
Ilavarasan Raju, Sridhar Seshaiah Krishnan. Synthesis of 6-
Fluoro-1,4-Dihydro-4-Oxo-Quinoline-3-carboxylic acid 
derivatives as potential antimicrobial agents. Eur J Med Chem 
2003;38:1001-4.  
41. HU Guo-Qiang, Zhang Zhong Quan, Huang Wen Long, Zhang Hui 
Bin, Huang Sheng Tang. Synthesis and antibacterial activity of 
new tetracyclic triazolothiadiazino (FQ)s. Chin Chem Lett 
2004;1:23-5. 
42. Liu Bo, Yang Chun-Hao, XuGuang-Yu, Zhu Yong-Hong, Cui Jing-
Rong, Wu Xi-Han. Syntheses of quinolone hydrochloride 
enantiomers from synthons (R)-and (S)-2-methylpiperazine. 
Bioorg Med Chem Lett 2005;13:2451-8. 
43. Yue-Ling Zhao, Yeh-Long Chen, Jia-YuhSheu, I-Li Chen, Tai-Chi 
Wangc, Cherng-Chyi Tzenga. Synthesis and antimycobacterial 
evaluation of certain (FQ) derivatives. Bioorg Med Chem Lett 
2005;13:3921-6. 
44. Foroumadi Alireza, Ghodsi Shahram, Emami, Najjari Somayyeh, 
Samadi Nasrin, Faramarzi Mohammad Ali, et al. Synthesis and 
antibacterial activity of new (FQ)s containing a substituted N-
(Phenethyl) piperazine moiety. Bioorg Med Chem Lett 
2006;16:3450-4.  
45. Talah AK, Gadad. Synthesis, Antibacterial and antitubercular 
activities of some 7-[4-(5-Amino-[1,3,4]Thiadiazole-2-
Sulfonyl (- Piperazin-1-Yl] fluoroquinolonic derivatives. Eur J 
Med Chem 2006;41:918-24.  
46. Prabodh Chander Sharma, Sandeep Jainb. Synthesis and in-vitro 
antibacterial activity of some novel n-nicotinoyl-1-ethyl-6-
fluoro-1,4-dihydro-7-piperazin-1-yl-4-oxoquinoline-3-
carboxylates. Acta Poloniae Pharm Drug Res 2008;65:551-7.  
47. Pokrovskaya Varvara, Belakhov Valery, Hainrichson Mariana, 
Yaron Sima, Baasov Timor. Design, Synthesis, and evaluation of 
noval (FQ)-Aminoglycoside hybrid antibiotics. J Med Chem 
2009;52:2243-54.  
48. Lucia Pintilie, Catalina Negut, C Oniscu, MT Caproiu, M 
Nechifor, Luminitaiancu, et al. Synthesis and antibacterial 
activity of some novel quinolones. Rom Biotechnol Lett 
2009;14:4756-67.  
49. Raed A, Al-Qawasmeh, Jalal A Zahra, Franca Zani, Paola Vicini, 
Roland Boese, et al. Synthesis and antibacterial activity of 9-
cyclopropyl-4-fluoro-6-oxo-6,9-dihydro-[1,2,5]thiadiazolo [3,4-
h]quinoline-7-carboxylic acid and its ethyl ester. ARKIVOC 
2009;12:322-36.  
50. Akhiles Roy, SM Sardar, BU Salve, DD Rishi Pathak. Studies on 
synthesis and biological evaluation of some substituted (FQ)s. 
Int J Chem Tech Res 2009;1:34-45.  
51. Ghodsi Shahram, Fouladi Shahrbanoo, Safari Hamze Ali, Ganji 
Masood Taghi. Synthesis and characterization of new (FQ)s 
containing an n substituted piperazine. Asian J Org Chem 
2009;21:3037-40.  
52. Shaikh Anwar R, Giridhar Rajani, Megraud Francis, Yadav 
Mange Ram. Metalloantibiotics: synthesis, characterization and 
antimicrobial evaluation of bismuth-fluroquinolone complex 
against helicobacter pyroli. Acta Pharm 2009;59:259-71.  
53. Taghi-Ganji Karim Masood. Synthesis and characterization of 
new derivative of norfloxacin-containing an n substituted 
piperazine moiety. Asian J Org Chem 2009;21:3851-4.  
54. Vincenet T, Andriole. The Quinolones. 4th ed. California: 
ACADIMIC PRESS; 2000. 
55. Shanmugam Srinivasan, Shweta Gupta, Ruchi Marwah, P 
Manisankar, Rupesh Kumar. Synthesis, Characterization and in 
vitro biological studies of novel N-Aryl piperazinyl (FQ)s. Res J 
Pharm Biol Chem Sci 2010;1:208-19.  
56. Om Prakash, Prabodh Chander, Sharma Sandeep Jain. Synthesis 
and antibacterial evaluation of novel (FQ) derivatives. Int Proc 
Chem Biol Environ Eng 2011;5:1-5. 
Sabbagh et al. 
Int J Pharm Pharm Sci, Vol 8, Issue 1, 67-75 
75 
57. Rajnish Kumar, Ashwani Kumar, Sandip Jain, Darpan Kaushik. 
Synthesis, antibacterial evaluation and QSAR studies of 7-[4-(5-
aryl-1,3,4-oxadiazole-2-yl)piperazinyl] quinolone derivatives. 
Eur J Med Chem 2011;46:3543-50.  
58. Najma Sultana, Muhammad Saeed Arayne, Syeda Bushra 
Shakeb Rizvi, Urooj Haroon. Synthesis, Characterization, and 
biological evaluation of ciprofloxacin carboxamide analogues. 
Bull Korean Chem Soc 2011;32:483-8.  
59. Negar Mohammad hosseini, Zahra Alipanahi, Eskandar Alipour, 
Saeed Emami, Mohammad Ali Faramarzi, Nasrin Samadi, et al. 
Synthesis and antibacterial activity of novel levofloxacin 
derivatives containing a substituted thienylethyl moiety. Daru J 
Pharm Sci 2012;20:1-6.  
60. SN Pandeya, Ranjana, Meena K Yadav. Synthesis and 
antimicrobial activity of ciprofloxacin schiff and mannich bases. 
Int J Pharm Tech Res 2012;4:778-85.  
61. Jubie, R Kalirajan, Pavan Kumar Yadav. Design, Synthesis and 
docking studies of a novel ciprofloxacin analogue as an 
antimicrobial AGENT. EJ Chem 2012;9:980-7.  
62. Sahu Susanta Kumar, Pandeya Surendra Nath, Pathak Ashish 
Kumar. In-silico identification and molecular docking studies of 
quinolone resistance determining region (QRDR) of E. coli DNA 
Gyrase-A with ofloxacin schiff bases. Int J Pharm Tech Res 
2013;5:1791-9.  
63. Saeed Emami, Ebrahim Ghafouri, Mohammad Ali Faramarzi, 
Nasrin Samadi, Hamid Irannejad, et al. Mannich bases of 7-
piperazinylquinolones and kojic acid derivatives: synthesis, in 
vitro antibacterial activity and in silico study. Eur J Med Chem 
2013;68:181-7. 
64. M Jeyanthi, BR Venkatraman. Synthesis and biological 
evaluation of novel 7-mercaptobenzimidazolyl (FQ)s. Int J 
Chem Tech Res 2014;6:1246-50.  
65. Mehul M Patel, Laxman J Patel. Design, Synthesis, Molecular 
docking, and antibacterial evaluation of some novel 
fluoroquinolone derivatives as potent antibacterial agent. Sci 
World J 2014. org/10.1155/2014/897187. [Article in Press] 
66. ACD/Chem Sketch Freeware, version 10. 00, Advanced 
Chemistry Development, Inc. Toronto, ON, Canada; 2012.  
67. Open Babel Freeware. Available from: www.vcclab.org/ 
lab/babel/start.html last view. [Last accessed on 01 May 2015]. 
68. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental 
and computational approaches to estimate solubility and 
permeability in drug discovery and development settings. 
Adv Drug Delivery Rev 2001;46:23–6.  
69. Edward H Kerns, Li Di. Drug-like properties: concepts, 
Structure design and methods: from ADME to toxicity 
optimization. 1st ed. Academic Press; 2008. p. 120-6.  
70. Molinspiration cheminformatics. Molinspiration; 2010. 
Available from: http://www.molinspiration.com/cgi-bin/ 
properties. [Last accessed on 26 Mar 2015]. 
71. Christopher A. Experimental and computational approaches to 
estimate solubility and permeability in drug discovery and 
development settings. Adv Drug Delivery Rev 200;46:23-6.  
72. Kai-Cheng Hsu, Yen-Fu Chen, Shen-Rong Lin, Jinn-Moon Yang. 
iGEMDOCK: a graphical environment of enhancing GEMDOCK 
using pharmacological interactions and post-screening 
analysis, BMC Bioinf 2011;12:1-11.  
73. Jinn-Moon Yang. Graphical-automatic drug design system for 
docking, screening and post-analysis. Department of Biological 
Science and Technology & Institute of Bioinformatics National 
Chiao Tung University; 2008. p. 1-69.  
74. Balavignesh V, Srinivasan E, Ramesh Babu NG. Molecular 
docking study ON NS5B polymerase of hepatitis virus by 
screening of volatile compounds from Acacia concinna and 
ADMET prediction. Int J Pharm Life Sci 2013;4:2548-58.  
75. D Gnanslin Sheeba, V Subha, K Suseela Gomathi, T Citarasu. 
Virtual docking studies of flavonoid compound against cell wall 
proteins of mycobacterium tuberculosis. Asian J Pharm Res Dev 
2013;1:88-97.  
76. Malik Mohammed, Adil Mustufa, Shubhra Chandra, Saima 
Wajid. Homology modeling and molecular docking analysis of 
human RAC-alpha serine/threonine protein kinase. 
Int J Pharma Bio Sci 2014;5:1033-42.  
77. Rini Abraham, Nisha NC, George K Varghese, Sreekumar S. 
Molecular docking of terminalia cuneata on cholesteryl-esteras. 
Int J Computational Bioinf In Silico Modeling 2014;3:324-9. 
 
